SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida, Aspergillus and Pneumocystis species.
Oqokelwe ukuthola umkhiqizo we-SCYNEXIS, ibrexafungerp (phambilini obaziwa njenge-SCY-078), uyinhlangano yokulwa nokukhunta kwenoveli  IV / umenzeli ongahambisani nefangali ngomlomo kuyiSigaba wesi-3 sokuthuthukiswa kwemitholampilo kanye nokwelashwa ngaphambi kokwelashwa kwezifo eziningi eziyingozi nezisongela impilo nezibangelwa izinhlobo eziyiKhandida, Aspergilasi  neNyumothayistisi .